Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.54 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425786 | 0.89 | SCN9A (0.54) | SCN9ASCN10ACYP3A4XIAP | |
| SCHEMBL4425777 | 0.89 | SCN9A (0.54) | SCN9ASCN10ACYP3A4XIAP | |
| SCHEMBL4246920 | 0.86 | SCN9A (0.51) | SCN9ASCN10ACYP3A4XIAP | |
| SCHEMBL4246925 | 0.86 | SCN9A (0.51) | SCN9ASCN10ACYP3A4XIAP | |
| SCHEMBL4427738 | 0.85 | SCN9A (0.55) | SCN9ASCN10A | |
| SCHEMBL4427745 | 0.85 | SCN9A (0.55) | SCN9ASCN10A | |
| SCHEMBL13310794 | 0.83 | SCN9A (0.75) | SCN9A | |
| SCHEMBL6177871 | 0.83 | ACE (0.39) | SCN9A | |
| SCHEMBL6177673 | 0.79 | ACE (0.38) | SCN9A | |
| SCHEMBL4427298 | 0.79 | SCN9A (0.53) | SCN9ASCN10AXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711470-B1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7160875-B2 | Malonamide derivatives | HOFFMANN-LA RACHE INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1711470-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005023772-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | BACE1, BACE2, APP | SCN9A 599/4885SCN10A 613/4885CYP3A4 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.